HK Stock Market Move | IMMUNEONCO-B(01541) increases by over 5%, core product IMM01 expected to submit preBLA application by the end of the year.

IMMUNEONCO-B(01541) rose more than 5%, as of the time of writing, it rose by 5.11% to HK$4.94, with a turnover of HK$8.3481 million. On the news front, on the evening of January 21, Yimingonco announced that the company had successfully completed the recruitment of 104 patients for the Phase III clinical trial of IMM01 (telaprevir) for first-line treatment of chronic myelomonocytic leukemia (CMML) by December 31, 2025, and is expected to complete the recruitment of 132 patients needed for the mid-term analysis by the end of March 2026. In addition, the company plans to submit a preBLA application by the end of 2026, and its Phase Ib/II study in atherosclerosis will also advance to the proof-of-concept stage. As of the announcement date, the board confirmed that the group's business operations and clinical development are normal, and there have been no significant adverse changes in the group's business operations and financial condition. It is worth mentioning that, according to the disclosure on Yimingonco's public account, recently, a team of three from Yimingonco attended the 44th annual J.P. Morgan Healthcare Conference, where the company's founder, chairman, CEO, and CSO Dr. Tian Wenzhi provided a comprehensive introduction to the company's development and significant project progress at the Biotech Showcase. Dr. Tian Wenzhi and the company's executive team had intensive meetings with over ten multinational pharmaceutical and biotechnology companies during the conference, and have established in-depth communication with multiple potential partners after the conference. The feedback has been positive, and substantial progress is expected in 2026, injecting new momentum into the global pipeline of the company.